(Total Views: 737)
Posted On: 07/04/2020 2:14:04 PM
Post# of 155666
Here is a clinical trial that will help build scientific consensus.
www.clinicaltrials.gov/ct2/show/NCT04334928
Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS)
Detailed Description:
This study aims to assess the efficacy of a daily single dose of TDF (245 mg)/FTC (200 mg), a daily single dose of HC (200 mg), a daily single dose of TDF (245 mg)/FTC (200 mg) plus HC (200 mg) versus placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing clinical severity COVID-19 among hospital healthcare workers aged 18 to 70 years in public and private hospitals in Spain.
Briefly, 4.000 participants will be assigned to one of the 4 groups, through 1:1:1:1 randomization. Duration of prophylactic treatment will be 12 weeks from early April 2020 till early July 2020. Follow up of participants will continue up to 4 weeks after last dose of treatment. All participants will be assessed on a monthly basis. Interim analyses will be performed on monthly bases.
I take the Ford retrospective study with a grain of salt. I believe that part of the Ford treatment protocol was to screen out patients with contraindications for HCQ (ie. heart issues, etc.). I would think that the study has normalized for those differences but don't see those statistics reported in the findings. That is one of many issues with a retrospective study.
www.clinicaltrials.gov/ct2/show/NCT04334928
Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS)
Detailed Description:
This study aims to assess the efficacy of a daily single dose of TDF (245 mg)/FTC (200 mg), a daily single dose of HC (200 mg), a daily single dose of TDF (245 mg)/FTC (200 mg) plus HC (200 mg) versus placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing clinical severity COVID-19 among hospital healthcare workers aged 18 to 70 years in public and private hospitals in Spain.
Briefly, 4.000 participants will be assigned to one of the 4 groups, through 1:1:1:1 randomization. Duration of prophylactic treatment will be 12 weeks from early April 2020 till early July 2020. Follow up of participants will continue up to 4 weeks after last dose of treatment. All participants will be assessed on a monthly basis. Interim analyses will be performed on monthly bases.
I take the Ford retrospective study with a grain of salt. I believe that part of the Ford treatment protocol was to screen out patients with contraindications for HCQ (ie. heart issues, etc.). I would think that the study has normalized for those differences but don't see those statistics reported in the findings. That is one of many issues with a retrospective study.
(1)
(0)
